Preventing and treating the complications of hormone therapy

Current Urology Reports

Volumn 6, Issue 3, 2005, Pages 217-223

  Kumar, Ravi J ^a   Barqawi, Al ^b   Crawford, E David ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

Advanced Prostate Cancer; Flutamide; Pamidronate; Prostate Cancer; Zoledronic Acid

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANEMIA; BODY COMPOSITION; DRUG EFFECT; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; MENTAL DISEASE; MUSCLE DISEASE; ORCHIECTOMY; OSTEOPOROSIS; PROSTATE TUMOR; REVIEW; SEXUAL DYSFUNCTION;

ANDROGEN ANTAGONISTS; ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; BODY COMPOSITION; GASTROINTESTINAL DISEASES; GYNECOMASTIA; HOT FLASHES; HUMANS; MALE; MENTAL DISORDERS; MUSCULAR DISEASES; ORCHIECTOMY; OSTEOPOROSIS; PROSTATIC NEOPLASMS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 32844456178     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-005-0010-9     Document Type: Article

References (69)

1. Huggins C, Hodges CV: Studies on prostate cancer, effect of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293 -297.
2. American Cancer Society: Cancer Facts & Figures: 2004. http://www.cancer.org/docroot/STT/stt_0.asp. Accessed November 2004.
3. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103 -106. DOI: 10.1016/S0140-6736(02)09408-4
4. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781–1788. DOI: 10.1056/NEJM199912093412401
5. Kirk D: MRC study: when to commence treatment in advanced prostate cancer. Prostate Cancer Prostatic Dis 1997, 1:11 -15. DOI: 10.1038/sj.pcan.4500207
6. Orwoll ES, Oviatt SK, McClung MR, et al.: The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990, 112:29 -34.
7. Selby PL, Davies M, Adams JE: Do men and women fracture bones at similar bone densities? Osteoporos Int 2000, 11:153 -157. DOI: 10.1007/PL00004177
8. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929 -1936. DOI: 10.1016/S0140-6736(02)08761-5
9. Center JR, Nguyen TV, Schneider D, et al.: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878 -882. DOI: 10.1016/S0140-6736(98)09075-8
10. Stepan JJ, Lachman M, Zverina J, et al.: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989, 69:523 -527. DOI: 10.1210/jcem-69-3-523
11. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157:439 -444. DOI: 10.1016/S0022-5347(01)65165-6
12. Oefelein MG, Ricchuiti V, Conrad W, et al.: Skeletal fracture associated with androgen suppression-induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724 -1728. DOI: 10.1016/S0022-5347(05)65661-3
13. Kiratli BJ, Srinivas S, Perkash I, Terris MK: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001, 57:127 -132. DOI: 10.1016/S0090-4295(00)00895-5
14. Daniell HW, Dunn SR, Ferguson DW, et al.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181 -186. DOI: 10.1016/S0022-5347(05)68000-7
15. Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656 -3661. The rate and sites of bone resorption and bone loss after 12 months treatment with LHRH analogues are highlighted in this study. Hip and distal radius were reported to have a significant BMD loss (3.3% and 5.3%, respectively). Spine and femoral neck were reported to be less affected by the castration levels of testosterone. This appears to be important when a structured prevention strategy is planned with the patient before initiation of hormonal treatment. DOI: 10.1210/jc.87.8.3656
16. Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238 -2245. This study highlights the pre-existing low BMD in men with prostate cancer prior to any hormonal ablation. It indirectly underscores the magnitude of the risk of fractures in men receiving hormonal therapy for prostate cancer as being a real and potentially lethal complication that prompts close monitoring and early prevention. DOI: 10.1002/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2
17. Falahati-Nini A, Riggs BL, Atkinson EJ, et al.: Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000, 106:1553 -1560. DOI: 10.1172/JCI10942
18. Behre HM, Kliesch S, Leifke E, et al.: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82:2386 -2390. DOI: 10.1210/jc.82.8.2386
19. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604 -610. DOI: 10.1056/NEJM200008313430902
20. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948 -955. An important concept was introduced in this prospective with intenttotreat study showing a significant beneficial effect of combining pamidronate with LHRH analogues early in the treatment of patients with advanced or recurrent prostate cancer with no bone metastasis. DOI: 10.1056/NEJMoa010845
21. Lipton A, Small E, Saad F, et al.: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002, 20(suppl_2):45 -54. DOI: 10.1081/CNV-120014886
22. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–12. This well performed multicenter study suggested a significant increase of BMD in the hip and spine (most common sites for fracture) when zoledronic acid was given to men receiving hormonal therapy for non-metastatic prostate cancer. DOI: 10.1097/01.ju.0000063820.94994.95
23. Eriksson S, Eriksson A, Stege R, Carlstrom K: Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995, 57:97 -99. DOI: 10.1007/BF00298427
24. Karling P, Hammar M, Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994, 152:1170 -1173.
25. Smith JA Jr: A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. J Urol 1994, 152:132 -134.
26. Miller JI, Ahmann FR: Treatment of castration-induced menopausal symptoms with low-dose diethylstilbestrol in men with advanced prostate cancer. Urology 1992, 40:499 -502. DOI: 10.1016/0090-4295(92)90401-H
27. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB: Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000, 55:97 -101. DOI: 10.1016/S0090-4295(99)00370-2
28. Loprinzi CL, Michalak JC, Quella SK, et al.: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994, 331:347 -352. DOI: 10.1056/NEJM199408113310602
29. Dawson NA, McLeod DG: Dramatic prostate-specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995, 153:1946 -1947. DOI: 10.1016/S0022-5347(01)67365-8
30. Quella SK, Loprinzi CL, Sloan J, et al.: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999, 162:98 -102. DOI: 10.1097/00005392-199907000-00024
31. Ellsworth JB. O’Rielly KJ, Thrasher JB: Depot-Provera therapy for hot flashes associated with hormonal treatment of advanced carcinoma of the prostate. J Urol 1998, 159(suppl):132.
32. Jeffery SM, Pepe JJ, Popovich LM, Vitagliano G: Gabapentin for hot flashes in prostate cancer. Ann Pharmacother 2002, 36:433 -436. DOI: 10.1345/aph.1A139
33. Cervenakov I, Kopecny M, Jancar M, et al.: ’Hot flush’: an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Int Urol Nephrol 2000, 32:77 -79. DOI: 10.1023/A:1007164319067
34. Hammar M, Frisk J, Grimas O, et al.: Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999, 161:853 -856. DOI: 10.1016/S0022-5347(01)61789-0
35. Murkies AL, Lombard C, Strauss BJ, et al.: Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995, 21:189 -195. DOI: 10.1016/0378-5122(95)00899-V
36. Scambia G, Mango D, Signorile PG, et al.: Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000, 7:105 -111.
37. Barton DL, Loprinzi CL, Quella SK, et al.: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998, 16:495 -500.
38. Pepping J: Black cohosh: Cimicifuga racemosa. Am J Health Syst Pharm 1999, 56:1400 -1402.
39. Jacobson JS, Troxel AB, Evans J, et al.: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001, 19:2739 -2745.
40. Moyad MA: Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: re-evaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002, 59:20 -33. DOI: 10.1016/S0090-4295(02)01641-2
41. Tamir S, Eizenberg M, Somjen D, et al.: Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001, 78:291 -298. DOI: 10.1016/S0960-0760(01)00093-0
42. Langenstroer P, Porter HJ II, McLeod DG, Thrasher JB: Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol 2004, 171:684 -686. This interesting study compared the direct GI toxicity of flutamide between irradiated and non-irradiated cases. The authors found no difference between the groups, suggesting that GI toxicity associated with flutamide does not increase after radiation. DOI: 10.1097/01.ju.0000106835.60202.81
43. Kackar RR, Desai HG: Hepatic failure with flutamide. Indian J Gastroenterol 2003, 22:149–150.
44. Strum SB, McDermed JE, Scholz MC, et al.: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933 -941.
45. Fonseca R, Rajkumar SV, White WL, et al.: Anemia after orchiectomy. Am J Hematol 1998, 59:230 -233. DOI: 10.1002/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2
46. Molinari PF: Erythropoietic mechanism of androgens: a critical review and clinical implications. Haematologica 1982, 67:442 -460.
47. McLeod DG, Iversen P: Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000, 56:713 -720. DOI: 10.1016/S0090-4295(00)00823-2
48. Hedlund PO: Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens. Prostate Suppl 2000, 10:32 -37. DOI: 10.1002/1097-0045(2000)45:10+<32::AID-PROS7>3.0.CO;2-V
49. Gagnon JD, Moss WT, Stevens KR: Pre-estrogen breast irradiation for patients with carcinoma of the prostate: a critical review. J Urol 1979, 121:182 -184.
50. Serels S, Melman A: Tamoxifen as treatment for gynecomastia and mastodynia resulting from hormonal deprivation. J Urol 1998, 159:1309. DOI: 10.1016/S0022-5347(01)63595-X
51. Auclerc G, Antoine EC, Cajfinger F, et al.: Management of advanced prostate cancer. Oncologist 2000, 5:36 -44. DOI: 10.1634/theoncologist.5-1-36
52. Baumgartner RN, Waters DL, Gallagher D, et al.: Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999, 107:123 -136. DOI: 10.1016/S0047-6374(98)00130-4
53. Morley JE, Baumgartner RN, Roubenoff R, et al.: Sarcopenia. J Lab Clin Med 2001, 137:231 -243. DOI: 10.1067/mlc.2001.113504
54. Brodsky IG, Balagopal P, Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996, 81:3469 -3475. DOI: 10.1210/jc.81.10.3469
55. Stone P, Hardy J, Huddart R, et al.: Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000, 36:1134 -1141. DOI: 10.1016/S0959-8049(00)00084-8
56. Segal RJ, Reid RD, Courneya KS, et al.: Resistance exercise in men receiving androgen-deprivation therapy for prostate cancer. J Clin Oncol 2003, 21:1653 -1659. This prospective study confirmed the importance of changes in lifestyle and, in particular, resistance exercise value in reducing fatigue and improving quality of life in men with prostate cancer receiving hormonal treatment. This should be highlighted by the treating physician before starting hormonal manipulation in these men. DOI: 10.1200/JCO.2003.09.534
57. Tan RS: Andropause and testosterone supplementation for cognitive loss. J Androl 2002, 23:45 -46.
58. Green HJ, Pakenham KI, Headley BC, et al.: Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized, controlled trial. BJU Int 2002, 90:427 -432. A systematic investigation of altered cognitive function due to the use of LHRH analogue in men with prostate cancer. It details the effect on memory, attention, and executive functions. These parameters of cognitive function as a risk of hormonal suppression are rarely discussed with the potential patients with prostate cancer. DOI: 10.1046/j.1464-410X.2002.02917.x
59. Higano CS, Ellis W, Russell K, Lange PH: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996, 48:800 -804. DOI: 10.1016/S0090-4295(96)00381-0
60. Tayek JA, Heber D, Byerley LO, et al.: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990, 39:1314 -1319. DOI: 10.1016/0026-0495(90)90190-N
61. Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen-deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599 -603. DOI: 10.1210/jc.87.2.599
62. Seidell JC, Bjorntorp P, Sjostrom L, et al.: Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990, 39:897–901. DOI: 10.1016/0026-0495(90)90297-P
63. Bergman B, Damber JE, Littbrand B, et al.: Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy, or oestrogens. Br J Urol 1984, 56:64 -69. DOI: 10.1111/j.1464-410X.1984.tb07166.x
64. Basaria S, Lieb J II, Tang AM, et al.: Long-term effects of androgen-deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779 -786. DOI: 10.1046/j.1365-2265.2002.01551.x
65. Marumo K, Baba S, Murai M: Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999, 6:19 -23. DOI: 10.1046/j.1442-2042.1999.06128.x
66. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54 -61.
67. Rashid MH, Chaudhary UB: Intermittent androgen-deprivation therapy for prostate cancer. Oncologist 2004, 9:295 -301. DOI: 10.1634/theoncologist.9-3-295
68. Smith MR, Fallon MA, Goode MJ: Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003, 61:127 -131. DOI: 10.1016/S0090-4295(02)02006-X
69. Lee KL, Terris MK: Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 2003, 62:351.